- Home
- WOLF vs AVIR Comparison
WOLF vs AVIR Comparison
Compare WOLF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOLF | AVIR |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.2M | 450.9M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WOLF | AVIR |
|---|---|---|
| Price | $25.57 | $5.41 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.33 | $10.00 |
| AVG Volume (30 Days) | ★ 3.2M | 281.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $0.39 | $2.46 |
| 52 Week High | $36.60 | $6.45 |
Technical Indicators
Market Signals| Indicator | WOLF | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 44.39 |
| Support Level | $15.86 | $5.03 |
| Resistance Level | $34.29 | $6.37 |
| Average True Range (ATR) | 3.39 | 0.23 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 35.00 | 19.46 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.